questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Utilisations thérapeutiques
Agents hématologiques
Coagulants
Hémostatiques
Hémostatiques : Questions médicales fréquentes
Termes MeSH sélectionnés :
Neovascularization, Pathologic
Diagnostic
5
Troubles de la coagulation
Tests de coagulation
Tests de coagulation
Hémostatiques
Saignement post-opératoire
Chirurgie
Antécédents médicaux
Anticoagulants
Symptômes
5
Hémorragie interne
Douleur abdominale
Troubles de la coagulation
Saignement
Réaction allergique
Hémostatiques
Prévention
5
Prévention des saignements
Interventions chirurgicales
Anticoagulants
Hygiène dentaire
Anticoagulants
Surveillance médicale
Hémophilie
Prévention des blessures
Éducation des patients
Hémostatiques
Traitements
5
Acide tranexamique
Vitamine K
Administration de médicaments
Hémostatiques
Saignement post-opératoire
Hémostatiques
Agents hémostatiques
Chirurgie
Effets secondaires
Hémostatiques
Complications
5
Réaction allergique
Antihistaminiques
Prévention des complications
Suivi médical
Signes d'alerte
Complications
Facteurs de risque
5
Facteurs de risque
Anticoagulants
Âge
Troubles de la coagulation
Médicaments
Anticoagulants
Maladies hépatiques
Coagulation
Comportements à risque
Alcool
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémostatiques : Questions médicales les plus fréquentes",
"headline": "Hémostatiques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémostatiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-08",
"dateModified": "2025-04-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémostatiques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Coagulants",
"url": "https://questionsmedicales.fr/mesh/D003029",
"about": {
"@type": "MedicalCondition",
"name": "Coagulants",
"code": {
"@type": "MedicalCode",
"code": "D003029",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.502.270"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agents d'inversion des anticoagulants",
"alternateName": "Anticoagulant Reversal Agents",
"url": "https://questionsmedicales.fr/mesh/D000089964",
"about": {
"@type": "MedicalCondition",
"name": "Agents d'inversion des anticoagulants",
"code": {
"@type": "MedicalCode",
"code": "D000089964",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.502.270.463.046"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Antifibrinolytiques",
"alternateName": "Antifibrinolytic Agents",
"url": "https://questionsmedicales.fr/mesh/D000933",
"about": {
"@type": "MedicalCondition",
"name": "Antifibrinolytiques",
"code": {
"@type": "MedicalCode",
"code": "D000933",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.502.270.463.091"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hémostatiques",
"alternateName": "Hemostatics",
"code": {
"@type": "MedicalCode",
"code": "D006490",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Patricia Davenport",
"url": "https://questionsmedicales.fr/author/Patricia%20Davenport",
"affiliation": {
"@type": "Organization",
"name": "Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, United States."
}
},
{
"@type": "Person",
"name": "Martha Sola-Visner",
"url": "https://questionsmedicales.fr/author/Martha%20Sola-Visner",
"affiliation": {
"@type": "Organization",
"name": "Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, United States."
}
},
{
"@type": "Person",
"name": "Reihaneh Haghniaz",
"url": "https://questionsmedicales.fr/author/Reihaneh%20Haghniaz",
"affiliation": {
"@type": "Organization",
"name": "Terasaki Institute for Biomedical Innovation, Los Angeles, California 90024, United States."
}
},
{
"@type": "Person",
"name": "Ali Khademhosseini",
"url": "https://questionsmedicales.fr/author/Ali%20Khademhosseini",
"affiliation": {
"@type": "Organization",
"name": "Terasaki Institute for Biomedical Innovation, Los Angeles, California 90024, United States."
}
},
{
"@type": "Person",
"name": "A B Zemlyanoy",
"url": "https://questionsmedicales.fr/author/A%20B%20Zemlyanoy",
"affiliation": {
"@type": "Organization",
"name": "Pirogov National Medical and Surgical Center of Ministry of Health of Russia, Moscow, Russia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Downregulation of PIK3IP1 in retinal microglia promotes retinal pathological neovascularization via PI3K-AKT pathway activation.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37550343",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-39473-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Novel theranostic approaches to neovascularized atherosclerotic plaques.",
"datePublished": "2023-05-02",
"url": "https://questionsmedicales.fr/article/37149970",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.atherosclerosis.2023.04.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hyperacute iris neovascularization following cataract surgery.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35801772",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MD.0000000000029356"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hyperreflective material in patients with non-neovascular pachychoroid disease.",
"datePublished": "2023-06-06",
"url": "https://questionsmedicales.fr/article/37280611",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-03011-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36828853",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-30146-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents hématologiques",
"item": "https://questionsmedicales.fr/mesh/D006401"
},
{
"@type": "ListItem",
"position": 6,
"name": "Coagulants",
"item": "https://questionsmedicales.fr/mesh/D003029"
},
{
"@type": "ListItem",
"position": 7,
"name": "Hémostatiques",
"item": "https://questionsmedicales.fr/mesh/D006490"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémostatiques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémostatiques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémostatiques",
"description": "Comment diagnostiquer un trouble de la coagulation ?\nQuels signes indiquent un besoin d'hémostatiques ?\nQuels tests pour évaluer l'efficacité des hémostatiques ?\nComment évaluer un saignement post-opératoire ?\nQuels antécédents médicaux sont pertinents ?",
"url": "https://questionsmedicales.fr/mesh/D006490?mesh_terms=Neovascularization,+Pathologic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémostatiques",
"description": "Quels sont les symptômes d'un saignement excessif ?\nComment reconnaître une hémorragie interne ?\nQuels signes d'alerte pour les troubles de la coagulation ?\nQuels symptômes d'une réaction aux hémostatiques ?\nComment identifier une thrombose ?",
"url": "https://questionsmedicales.fr/mesh/D006490?mesh_terms=Neovascularization,+Pathologic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémostatiques",
"description": "Comment prévenir les saignements chez les patients à risque ?\nQuels conseils pour éviter les saignements ?\nComment surveiller les patients sous anticoagulants ?\nQuelles mesures pour les patients hémophiles ?\nComment éduquer les patients sur les hémostatiques ?",
"url": "https://questionsmedicales.fr/mesh/D006490?mesh_terms=Neovascularization,+Pathologic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémostatiques",
"description": "Quels sont les principaux hémostatiques utilisés ?\nComment administrer des hémostatiques ?\nQuels traitements pour les saignements post-opératoires ?\nQuand utiliser des agents hémostatiques locaux ?\nQuels sont les effets secondaires des hémostatiques ?",
"url": "https://questionsmedicales.fr/mesh/D006490?mesh_terms=Neovascularization,+Pathologic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémostatiques",
"description": "Quelles complications peuvent survenir avec les hémostatiques ?\nComment gérer une réaction allergique aux hémostatiques ?\nQuels risques de thrombose avec des hémostatiques ?\nComment prévenir les complications liées aux hémostatiques ?\nQuels signes d'alerte pour des complications ?",
"url": "https://questionsmedicales.fr/mesh/D006490?mesh_terms=Neovascularization,+Pathologic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémostatiques",
"description": "Quels facteurs augmentent le risque de saignement ?\nComment l'âge influence-t-il le risque de saignement ?\nQuels médicaments augmentent le risque de saignement ?\nComment les maladies hépatiques affectent-elles la coagulation ?\nQuels comportements augmentent le risque de saignement ?",
"url": "https://questionsmedicales.fr/mesh/D006490?mesh_terms=Neovascularization,+Pathologic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un trouble de la coagulation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins comme le temps de prothrombine et le temps de saignement sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un besoin d'hémostatiques ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements excessifs, des ecchymoses fréquentes ou des saignements prolongés peuvent indiquer un besoin."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'efficacité des hémostatiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "On utilise des tests comme le temps de thrombine et le temps de céphaline activé."
}
},
{
"@type": "Question",
"name": "Comment évaluer un saignement post-opératoire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "On examine la quantité de sang perdu et la durée du saignement après la chirurgie."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont pertinents ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de troubles de la coagulation ou d'utilisation d'anticoagulants sont importants."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'un saignement excessif ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des ecchymoses, des saignements de nez fréquents et des gencives qui saignent."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hémorragie interne ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales, des vertiges ou une pâleur peuvent indiquer une hémorragie interne."
}
},
{
"@type": "Question",
"name": "Quels signes d'alerte pour les troubles de la coagulation ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements prolongés après une coupure ou des saignements inhabituels sont des signes d'alerte."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une réaction aux hémostatiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons ou des difficultés respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment identifier une thrombose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un gonflement, une douleur ou une rougeur dans une jambe peuvent indiquer une thrombose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les saignements chez les patients à risque ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "On peut prescrire des hémostatiques préventifs avant des interventions chirurgicales."
}
},
{
"@type": "Question",
"name": "Quels conseils pour éviter les saignements ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les anticoagulants non prescrits et maintenir une bonne hygiène dentaire."
}
},
{
"@type": "Question",
"name": "Comment surveiller les patients sous anticoagulants ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des contrôles réguliers de la coagulation sanguine sont nécessaires pour ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour les patients hémophiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients hémophiles doivent éviter les sports de contact et suivre un traitement préventif."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les hémostatiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer sur l'utilisation correcte, les effets secondaires et l'importance du suivi médical."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux hémostatiques utilisés ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les hémostatiques courants incluent l'acide tranexamique et la vitamine K."
}
},
{
"@type": "Question",
"name": "Comment administrer des hémostatiques ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intraveineuse ou topique selon le type."
}
},
{
"@type": "Question",
"name": "Quels traitements pour les saignements post-opératoires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "On peut utiliser des compresses, des sutures ou des hémostatiques pour contrôler le saignement."
}
},
{
"@type": "Question",
"name": "Quand utiliser des agents hémostatiques locaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont utilisés lors de chirurgies pour contrôler les saignements au site opératoire."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des hémostatiques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions allergiques, des nausées ou des thromboses."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les hémostatiques ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des thromboses, des réactions allergiques ou des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique aux hémostatiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il faut arrêter le traitement et administrer des antihistaminiques ou des corticostéroïdes si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels risques de thrombose avec des hémostatiques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation excessive d'hémostatiques peut augmenter le risque de thrombose veineuse profonde."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux hémostatiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un ajustement des doses peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels signes d'alerte pour des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des essoufflements ou des gonflements doivent alerter immédiatement."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de saignement ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, l'utilisation d'anticoagulants et certaines maladies augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque de saignement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées ont un risque accru de troubles de la coagulation et de saignements."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque de saignement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticoagulants, les anti-inflammatoires non stéroïdiens et certains antibiotiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Comment les maladies hépatiques affectent-elles la coagulation ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies hépatiques peuvent altérer la production de facteurs de coagulation, augmentant le risque de saignement."
}
},
{
"@type": "Question",
"name": "Quels comportements augmentent le risque de saignement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La consommation excessive d'alcool et le tabagisme peuvent augmenter le risque de saignement."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 03/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, United States.
Publications dans "Hémostatiques" :
2 publications dans cette catégorie
Affiliations :
Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, United States.
Publications dans "Hémostatiques" :
2 publications dans cette catégorie
Affiliations :
Terasaki Institute for Biomedical Innovation, Los Angeles, California 90024, United States.
Publications dans "Hémostatiques" :
2 publications dans cette catégorie
Affiliations :
Terasaki Institute for Biomedical Innovation, Los Angeles, California 90024, United States.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Pirogov National Medical and Surgical Center of Ministry of Health of Russia, Moscow, Russia.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiology, Toyokawa City Hospital, 23 Nozi Yawata-cho, Toyokawa City, Aichi, 442-8561, Japan. nnhk110184@kpe.biglobe.ne.jp.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiology, Toyokawa City Hospital, 23 Nozi Yawata-cho, Toyokawa City, Aichi, 442-8561, Japan.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiology, Toyokawa City Hospital, 23 Nozi Yawata-cho, Toyokawa City, Aichi, 442-8561, Japan.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiology, Toyokawa City Hospital, 23 Nozi Yawata-cho, Toyokawa City, Aichi, 442-8561, Japan.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiology, Toyokawa City Hospital, 23 Nozi Yawata-cho, Toyokawa City, Aichi, 442-8561, Japan.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiology, Toyokawa City Hospital, 23 Nozi Yawata-cho, Toyokawa City, Aichi, 442-8561, Japan.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiology, Toyokawa City Hospital, 23 Nozi Yawata-cho, Toyokawa City, Aichi, 442-8561, Japan.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, 96702Beijing Institute of Radiation Medicine, Beijing, PR China.
96702State Key Laboratory of NBC Protection for Civilian, Beijing, PR China.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, 96702Beijing Institute of Radiation Medicine, Beijing, PR China.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, 96702Beijing Institute of Radiation Medicine, Beijing, PR China.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, 96702Beijing Institute of Radiation Medicine, Beijing, PR China.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, 96702Beijing Institute of Radiation Medicine, Beijing, PR China.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, 96702Beijing Institute of Radiation Medicine, Beijing, PR China.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, 96702Beijing Institute of Radiation Medicine, Beijing, PR China.
Publications dans "Hémostatiques" :
1 publication dans cette catégorie
Affiliations :
96702State Key Laboratory of NBC Protection for Civilian, Beijing, PR China.
Publications dans "Hémostatiques" :
Retinal pathological neovascularization involves endothelial cells, pericytes, photoreceptor cells, ganglion cells, and glial cells, whose roles remain unclear. Using the Scissor algorithm, we found t...
As the global burden of atherosclerotic cardiovascular disease continues to rise, there is an increased demand for improved imaging techniques for earlier detection of atherosclerotic plaques and new ...
We describe a case of acute neovascularization of the iris after uneventful cataract surgery....
A 78-year-old man visited our clinic for cataract surgery and glaucoma management....
The patient underwent bilateral laser iridotomy 4 years ago. On ocular examination, the best-corrected visual acuity was no light perception in the right eye and 20/100 in the left eye. We observed ps...
The patient underwent cataract surgery in the left eye without complications....
The day after surgery we observed 360° of neovascularization in the iris and aggravated hemi-CRVO with macular edema. Therefore, we administered intravitreal bevacizumab in the left eye, after which t...
Cataract surgery can rapidly aggravate hemi-CRVO and cause iris neovascularization, which is responsive to bevacizumab....
This study aimed to report eleven cases of non-neovascular pachychoroid disease with hyperreflective material (HRM) that occurred in Japanese patients....
A retrospective review of data from eleven patients who had non-neovascular retinal pigment epithelium (RPE) protrusion with HRM in the neurosensory retina between March 2017 and June 2022 was conduct...
All cases had RPE protrusion and HRM with dilated choroidal veins, which were characteristic of pachychoroid disease. However, none of the cases had macular neovascularization (MNV). In 9 eyes (81.8%)...
There are some cases of non-neovascular pachychoroid disorder with HRM, which might be a new entity of pachychoroid spectrum disease or an early stage of PPE or FCE. These cases should not be misdiagn...
We previously reported one-year results of a treat-and-extend (TAE) regimen with intravitreal brolucizumab for 68 eyes with treatment-naïve neovascular age-related macular degeneration (nAMD) associat...
Diabetic retinopathy (DR) is a common complication of diabetes, and recent findings have shown that long noncoding RNAs (lncRNAs) may be involved in its pathogenesis. Through bioinformatics analysis, ...
We used RT‒PCR to assess the expression levels of lncRNA ATP2B2-IT2 and vascular endothelial growth factor (VEGF) in HRMECs under normal glucose (5.5 mmol/L) and high glucose (30 mmol/L) conditions. H...
RT‒PCR revealed that the expression levels of the lncRNA ATP2B2-IT2 and VEGF were greater in the HG group than in the NG group (P < 0.05). After silencing of the lncRNA ATP2B2-IT2, the expression of V...
LncRNA ATP2B2-IT2 may promote the proliferation, migration and neovascularization of HRMECs under high-glucose conditions....
To report the cumulative incidence and risk factors of second eye involvement after diagnosis of myopic macular neovascularization (MNV) in the first eye....
Retrospective analysis of longitudinal data from a tertiary hospital in the Netherlands....
Patients with high myopia (spherical equivalent [SE] ≤ - 6 diopters [D]), of European ethnicity, who were diagnosed with active MNV lesion in 1 eye between 2005 and 2018. Fellow eyes were free of MNV ...
Incidence rate and 2-, 5-, and 10-year cumulative incidences were calculated; hazard ratios (HRs) of second eye involvement were analyzed for potential risk factors using Cox proportional hazard model...
Incidence of second eye involvement after onset of myopic MNV in the first eye....
We included 88 patients over a period of 13 years with a mean age of 58 ± 15 years, mean axial length of 30 ± 1.7 mm and SE -14 ± 4 D at baseline. Twenty-four fellow eyes (27%) developed a myopic MNV ...
Our study of high myopes of European descent shows very similar incidence rates for second eye myopic MNV compared with Asian studies. Our findings substantiate the importance for clinicians to monito...
The authors have no proprietary or commercial interest in any materials discussed in this article....
To examine the role of CCL14 in the neovascularization process and vulnerability progression within carotid plaques by investigating the mechanism of CCL14 regulation of VEGF-A....
We first performed histological analysis and immunohistochemical staining of human carotid plaque tissue to detect the expression of CCL14, JAK2, STAT3 and VEGF-A. We next examined the protein express...
Histological and Western blotting analysis of human carotid plaque samples showed that the expression of CCL14 and VEGF-A was higher in the vulnerable plaques than in stable plaques. In the in vitro c...
In the human carotid plaques, CCL14 promotes angiogenesis by upregulation of VEGF-A via JAK2/STAT3 pathway and thus drives the progression of carotid plaques vulnerability....
To report the incidence and risk factors associated with ocular neovascularization (NV) in patients with central retinal artery occlusion (CRAO)....
This retrospective study included patients diagnosed with acute CRAO in a single tertiary center. Medical charts were reviewed for ocular NV occurrences. We analyzed systemic and ocular conditions on ...
Eighty-seven eyes were eligible for this study. Among these, 13 eyes had ocular NV after CRAO, with an incidence of 15%. The prevalences of hypertension, diabetes mellitus, history of stroke, chronic ...
CKD and glaucoma history were significant risk factors for developing ocular NV after CRAO, particularly among patients that underwent dialysis....
Angiogenesis is the biological process in which existing blood vessels generate new ones and it is essential for body growth and development, wound healing, and granulation tissue formation. Vascular ...